ReviewNature reviews. Immunology2009
Harnessing invariant NKT cells in vaccination strategies.
Review in Nature reviews. Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 189 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
189 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic impact of invariant natural killer T cells in solid and hematological tumors; systematic review and meta-analysis.Cancer biomarkers : section A of Disease markers · 2024Pooled it
- Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.Frontiers in immunology · 2024Trial
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias.The Journal of experimental medicine · 2014Trial
- Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.Clinical and experimental immunology · 2014Trial
- Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.Journal of medicinal chemistry · 2026Review
- Deciphering the role of glycolipids as emerging therapeutic targets in EMT-driven cancer progression.Discover oncology · 2026Review
- A novel multi-epitope vaccine induces protective and therapeutic immunity against Helicobacter pylori.NPJ vaccines · 2026Article
- Development of a Self-Adjuvanting Influenza Peptide-Glycolipid Conjugate Inducing CD8Chembiochem : a European journal of chemical biology · 2026Article
- Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans.Immunology and cell biology · 2026Article
- Molecular mechanisms and clinical significance of the glioma metabolic-immune axis: a comprehensive review.Frontiers in immunology · 2026Review
- α-Galactosylceramide-expanded virtual memory CD8Frontiers in immunology · 2026Article
- Can invariant Natural Killer T cells drive B cell fate? a look at the humoral response.Frontiers in immunology · 2025Review
- NKT Hybridoma Cell Stimulation Assays to Evaluate Glycolipid Specificity and Processing.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Identification of Functional Immune Biomarkers in Breast Cancer Patients.International journal of molecular sciences · 2024Article
- Comprehensive Insight into the Functional Roles of NK and NKT Cells in HTLV-1-Associated Diseases and Asymptomatic Carriers.Molecular neurobiology · 2024Review
- Article
- Chemical synthesis and immunological evaluation of cancer vaccines based on ganglioside antigens and α-galactosylceramide.RSC medicinal chemistry · 2024Article
- Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.JHEP reports : innovation in hepatology · 2024Article
- State of play in the molecular presentation and recognition of anti-tumor lipid-based analogues.Frontiers in immunology · 2024Review
- Thymic development of human natural killer T cells: recent advances and implications for immunotherapy.Frontiers in immunology · 2024Review
129 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To optimize vaccination strategies, it is important to use protocols that can 'jump-start' immune responses by harnessing cells of the innate immune system to assist the expansion of antigen-specific B and T cells. In this Review, we discuss the evidence indicating that invariant natural killer T (iNKT) cells can positively modulate dendritic cells and B cells, and that their pharmacological activation in the presence of antigenic proteins can enhance antigen-specific B- and T-cell responses. In addition, we describe structural and kinetic analyses that assist in the design of optimal iNKT-cell agonists that could be used in the clinical setting as vaccine adjuvants.
Indexed as
Identifiers
19079136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.